Company Overview
Silexion Therapeutics Corp operates as a biopharmaceutical entity dedicated to the discovery and development of RNA interference (RNAi)-based cancer drugs and delivery systems specifically designed to treat malignant solid tumors. The company focuses on the treatment of solid tumors through its proprietary LODER delivery platform, utilizing advanced therapeutic approaches to address complex oncological challenges. Operating within the Healthcare sector and the Biotechnology industry, Silexion positions itself as a specialized player in a high-risk, high-reward field where innovation drives value creation. The company currently maintains a market capitalization of $4.06M and employs a workforce of 13 individuals, while reporting N/A for annual revenue due to its early-stage operational profile. These valuation and scale metrics indicate that Silexion is a micro-cap entity with limited revenue generation relative to its cash reserves, suggesting it is still in a phase where capital allocation prioritizes research and development over commercial expansion or profitability.
Financial Health
The company reported N/A for revenue over the trailing twelve months (TTM) and recorded a net income of $-11,912,000, resulting in an EBITDA of $-11,618,000. The gap between the non-existent revenue and the substantial negative net income reveals a cost structure dominated by high fixed costs associated with drug discovery and development rather than variable production expenses. Free cash flow stands at $-6,507,125, which signifies that the company is consuming cash to fund its operations and R&D initiatives, thereby limiting its current financial flexibility for external acquisitions or large-scale capital expenditures. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, reflecting the absence of commercial sales and the inability to generate a profit from revenue at this stage of the business lifecycle. On the balance sheet, the company holds $5.99M in cash against $2.04M in debt, supported by a debt-to-equity ratio of 78.22, which suggests a leveraged position relative to equity but maintains sufficient liquidity to meet obligations. The current ratio is 2.41, indicating that the company possesses 2.41 times more current assets than current liabilities, which points to a relatively strong short-term liquidity position despite the negative earnings. Return on Equity is listed as N/A due to the lack of positive earnings, while Return on Assets is -144.3%, a metric that mathematically reflects the erosion of asset value relative to the asset base caused by significant operating losses.
Valuation Assessment
The P/E Ratio (TTM) is N/A because the company has not generated positive earnings over the trailing twelve months, whereas the forward P/E is -1.91, a figure that implies the market is pricing in future earnings potential that has not yet materialized in historical data. The price-to-book ratio is 1.46, indicating that the market values the company at 46% above its book value, which may reflect investor optimism regarding the potential success of its RNAi technology despite current losses. The price-to-sales ratio is N/A as there are no sales figures available, and the EV/EBITDA stands at -0.01, suggesting that traditional valuation multiples based on profitability are not applicable for this pre-commercial entity. The stock has traded between a 52-week low of $1.20 and a 52-week high of $22.36, meaning the current price sits within this volatile range but requires specific calculation to determine the exact percentage distance from the highs or lows at any given moment. The beta value is -0.04, a highly unusual metric for equities that suggests the stock price moves inversely or with negligible correlation to the broader market, indicating extreme idiosyncratic risk rather than systematic market risk exposure.
Growth & Income
Revenue growth (YoY) and earnings growth (YoY) are both listed as N/A, preventing a direct comparison of whether earnings are growing faster or slower than revenue since no historical sales data exists to establish a growth trajectory. As a non-dividend payer, Silexion reports a dividend yield of N/A and a payout ratio of 0.0%, indicating that the company reinvests all available capital and earnings back into its research and development pipeline rather than distributing income to shareholders. The absence of dividend payments and the lack of historical growth rates summarize an overall growth and income profile characterized by a complete reliance on organic development and external capital sources to fuel expansion. This profile is typical for biotechnology firms in the discovery phase, where the primary objective is achieving product approval rather than generating immediate shareholder returns through dividends or earnings growth.